US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

Virios Therapeutics, Inc. - Common Stock (NQ:VIRI)

0.1550 UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Virios Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight ↗
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
News headline image
Virios Therapeutics Announces Second Quarter 2021 Financial Results and Provides Corporate Update
From Virios Therapeutics, Inc.
Via Business Wire
News headline image
Earnings Scheduled For August 12, 2021 ↗
Companies Reporting Before The Bell • Anavex Life Sciences (NASDAQ:AVXL) is estimated to report earnings for its third quarter. • ITeos Therapeutics (NASDAQ:ITOS... 
Via Benzinga
News headline image
Virios Therapeutics to Present at the SNN Network Summer Virtual Conference
From Virios Therapeutics, Inc. (VIRI)
Via Business Wire
News headline image
Virios Therapeutics Featured in Bloomberg TV Interview
From Virios Therapeutics, Inc. (VIRI)
Via Business Wire
News headline image
Virios Therapeutics to Report Second Quarter 2021 Financial Results and Provide Corporate Update on Thursday, August 12, 2021
From Virios Therapeutics, Inc. (VIRI)
Via Business Wire
Why Virios Therapeutics' Stock Is Trading Higher Today ↗
Virios Therapeutics' (NASDAQ:VIRI) shares ar... 
Via Benzinga
News headline image
Virios Therapeutics Highlights Clinical Sites Fully Operational in Phase 2b Fibromyalgia Study Featuring FDA “Fast Track” Review Designated Antiviral Therapy, Oral IMC-1
From Virios Therapeutics, Inc. (VIRI)
Via Business Wire
News headline image
Fibromyalgia Treatment: 3 Pillars that Set Virios Therapeutics Apart from the Rest ↗
The success of any company most often begins with a solid foundation and strong pillars. These two are essential ingredients to the growth of a company. Weak foundations or... 
Via Benzinga
News headline image
Virios Therapeutics Stock Moves Higher On Promising IMC-1 Safety Data In Mid-Stage Fibromyalgia Trial ↗
Virios Therapeutics Inc (NASDAQ: VIRI) has announced that data from its Phase 2a PRID-201 trial demonstrated that IMC-1 was better tolerated than placebo in... 
Via Benzinga
News headline image
Virios Therapeutics Highlights Safety Data from Phase 2a Fibromyalgia Trial at the International Association for the Study of Pain (IASP) World Congress
From Virios Therapeutics, Inc.
Via Business Wire
News headline image
62 Biggest Movers From Yesterday ↗
Gainers Aethlon Medical, Inc. (NASDAQ: AEMD) shares surged 388.2% to close at $10.79 on Wednesday in reaction to Zacks Article 'AEMD: First Ever In Vivo Removal Of COVID... 
Via Benzinga
News headline image
Virios Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating IMC-1 in Patients with Fibromyalgia
From Virios Therapeutics, Inc. (VIRI)
Via Business Wire
News headline image
48 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Aethlon Medical, Inc. (NASDAQ: AEMD) shares jumped 371% to $10.41 in reaction to Zacks Article 'AEMD: First Ever In Vivo Removal Of COVID Virus From Bloodstream Of An... 
Via Benzinga
News headline image
Virios Therapeutics Presents Phase 2a Fibromyalgia Trial Data on Efficacy Analyses of Key Secondary Endpoints at the EULAR European Congress of Rheumatology
From Virios Therapeutics, Inc. (VIRI)
Via Business Wire
News headline image
Virios Therapeutics Announces Oral Presentation of Clinical Data at Digestive Disease Week® (DDW)
From Virios Therapeutics, Inc.
Via Business Wire
News headline image
58 Biggest Movers From Yesterday ↗
Gainers BM Technologies, Inc. (NYSE: BMTX) shares climbed 26.4% to close at $11.82 on Tuesday after the company reported record Q1 results. Ultralife Corporation (NASDAQ: ULBI)... 
Via Benzinga
News headline image
Virios Therapeutics Announces First Quarter 2021 Financial Results and Provides Corporate Update
From Virios Therapeutics, Inc. (VIRI)
Via Business Wire
News headline image
Virios Therapeutics to Present at the Benzinga Global Small Cap Conference
From Virios Therapeutics, Inc.
Via Business Wire
News headline image
Virios Therapeutics to Report First Quarter 2021 Financial Results and Provide Corporate Update on Thursday, May 13, 2021
From Virios Therapeutics, Inc. (VIRI)
Via Business Wire
News headline image
Earnings Scheduled For May 13, 2021 ↗
Companies Reporting Before The Bell • CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report quarterly loss at $0.06 per share on revenue of $5.05 million. •... 
Via Benzinga
News headline image
Virios Therapeutics, Inc. Interview to Air on Bloomberg Television U.S. on the RedChip Money Report
From Virios Therapeutics, Inc. (VIRI)
Via Business Wire
News headline image
Virios Therapeutics to Present at the Needham Virtual Healthcare Conference
From Virios Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >